A Phase 2 interventional study of alpelisib and buparlisib in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 87 sites in 17 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.
Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 7 that started in 2014, is one of 15 in phase 2, and was the 7th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Novartis Pharmaceuticals
By country, each count listing its studies:
Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, alpelisib is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 5
First in 2010; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 340 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 44 across the 38 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 34th largest by enrollment of the 155 interventional ones that give a count, is one of 13 that started in 2014, is one of 39 in phase 2, and was the 102nd registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
7 of the studies testing alpelisib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05660083The Methodist Hospital Research InstituteAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | 2026-12-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies testing alpelisib in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
Drug: alpelisib
Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
Drug: buparlisib
Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
Drug: Placebo
BYL719 + Letrozole
Also known as: BYL719
BKM120 + Letrozole
Also known as: BKM120
Placebo (of BYL719 or BKM120) + Letrozole
Also known as: BYL719 Placebo, BKM120 Placebo
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort
Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.
Time frame: After 24 weeks of treatment
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort
Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.
Time frame: After 24 weeks of treatment
Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.
Time frame: After 24 weeks of treatment
Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.
Time frame: After 24 weeks of treatment
pCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Mutant Cohort Based on ctDNA
pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment
Time frame: After 24 weeks of treatment
pCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Wild-type Cohort Based on ctDNA
pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment
Time frame: After 24 weeks of treatment
Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.
Time frame: After 24 weeks of treatment
Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Breast conserving surgery is defined as the percentage of participants with no mastectomy following completion of 24 weeks of treatment. Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.
Time frame: After 24 weeks of treatment
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR
Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR.
Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days ) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Responders as Per pCR
Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: responders as per pCR
Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Non-responders as Per pCR
Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: non-responders as per pCR
Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA mutant cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.
Time frame: At the time of surgery (expected after 24 weeks of treatment)
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA wild-type cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.
Time frame: At the time of surgery (expected after 24 weeks of treatment)
Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Alpelisib PK Parameter: Cmax at Cycle 1 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Alpelisib and PK Parameter: Tmax at Cycle 1 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Alpelisib PK Parameter: Cmax at Cycle 4 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
Alpelisib PK Parameter: Tmax at Cycle 4 Day 1
Summary of primary PK parameters for alpelisib plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
Letrozole and PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
Summary of primary PK parameters for Letrozole plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Letrozole PK Parameter: Cmax at Cycle 1 Day 1
Summary of primary PK parameters for letrozole plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Letrozole PK Parameter: Tmax at Cycle 1 Day 1
Summary of primary PK parameters for letrozole plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Letrozole PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1
Summary of primary PK parameters for Letrozole plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Letrozole PK Parameter: Cmax at Cycle 4 Day 1
Summary of primary PK parameters for letrozole plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
Letrozole PK Parameter: Tmax at Cycle 4 Day 1
Summary of primary PK parameters for letrozole plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
Buparlisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
Summary of primary PK parameters for Buparlisib plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Buparlisib PK Parameter: Cmax at Cycle 1 Day 1
Summary of primary PK parameters for buparlisib plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Buparlisib PK Parameter: Tmax at Cycle 1 Day 1
Summary of primary PK parameters for buparlisib plasma concentration
Time frame: Cycle 1 Day 1 (each cycle is 28 days)
Buparlisib PK Parameter: AUClast at Cycle 4 Day 1
Summary of primary PK parameters for Buparlisib plasma concentration
Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Buparlisb PK Parameter: Cmax at Cycle 4 Day 1
Summary of primary PK parameters for buparlisib plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
Buparlisib PK Parameter: Tmax at Cycle 4 Day 1
Summary of primary PK parameters for buparlisib plasma concentration
Time frame: Cycle 4 Day 1 (each cycle is 28 days)
A total of approximately 320 patients were planned to be randomized: this was based on 60 patients per arm in each cohort (PIK3CA mutant and PIK3CA wild-type) for the alpelisib+letrozole and placebo+letrozole arms, plus the estimated number of patients randomized to buparlisib+letrozole arm at the time this arm was discontinued.
| Milestone | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole |
|---|---|---|---|
| Started | 131 | 83 | 126 |
| Completed | 94 | 44 | 109 |
| Not completed | 37 | 39 | 17 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Subject/guardian decision | 14 | 14 | 4 |
| Withdrew: Adverse event | 12 | 12 | 0 |
| Withdrew: Physician decision | 6 | 9 | 5 |
| Withdrew: Progressive disease | 4 | 3 | 7 |
| Withdrew: Death | 0 | 0 | 1 |
Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.
| Percentage of Participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort | 1.7 (0.2 to 6.3) | 3.0 (0.8 to 7.7) |
Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.
| Percentage of Participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort | 2.8 (0.8 to 7.3) | 1.7 (0.2 to 6.4) |
Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.
| Percentage of Participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort | 43.3 (34.6 to 52.4) | 44.8 (36.5 to 53.3) |
Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.
| Percentage of Participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort | 63.4 (55.1 to 71.0) | 61.0 (51.8 to 69.6) |
pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment
No measurements were reported for this outcome.
pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment
No measurements were reported for this outcome.
Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.
| Percentage of participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Breast conserving surgery | 56.7 (47.6 to 65.4) | 50.7 (42.2 to 59.2) |
| No Surgery | 15.0 (9.3 to 22.6) | 9.0 (4.8 to 15.2) |
Breast conserving surgery is defined as the percentage of participants with no mastectomy following completion of 24 weeks of treatment. Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.
| Percentage of participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Breast conserving surgery | 50.7 (42.5 to 58.9) | 62.7 (53.6 to 71.2) |
| No Surgery | 18.3 (12.5 to 25.6) | 8.5 (4.5 to 15.2) |
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR
| Percentage of positive cells | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Baseline | 5.0 (5 to 5) | 11.0 (5 to 17) |
| C1D15: % change from Baseline | -80.0 (-80 to -80) | 80.0 (80 to 80) |
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR.
| Percentage of positive cells | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Baseline | 14.0 (0 to 82) | 13.0 (3 to 89) |
| C1D15 % change from Baseline | -62.5 (-97 to 467) | -60.0 (-96 to 733) |
| EOT % change from Baseline | -51.2 (-94 to 400) | -60.0 (-97 to 223) |
Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: responders as per pCR
| Percentage of positive cells | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Baseline | 16.5 (3 to 30) | 20.0 (20 to 20) |
| C1D15: % change from Baseline | -80.0 (-80 to -80) | — |
| EOT % change from Baseline | -45.0 (-90 to 0) | — |
Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: non-responders as per pCR
| Percentage of positive cells | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Baseline | 16.0 (3 to 60) | 18.0 (4 to 85) |
| C1D15 % change from Baseline | -60.0 (-97 to 220) | -52.0 (-93 to 50) |
| EOT % change from Baseline | -60.0 (-90 to 190) | -71.1 (-100 to 250) |
Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA mutant cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.
| Number of participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort | 1 | 0 |
Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA wild-type cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.
| Number of participants | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort | 1 | 1 |
Summary of primary PK parameters for alpelisib plasma concentration
| ng*hr/mL | Alpelisib + Letrozole |
|---|---|
| AUC0-24 | 30800 ± 20.6 |
| AUClast | 27300 ± 68.6 |
Summary of primary PK parameters for alpelisib plasma concentration
| ng/mL | Alpelisib + Letrozole |
|---|---|
| Alpelisib PK Parameter: Cmax at Cycle 1 Day 1 | 3160 ± 25.3 |
Summary of primary PK parameters for alpelisib plasma concentration
| HR | Alpelisib + Letrozole |
|---|---|
| Alpelisib and PK Parameter: Tmax at Cycle 1 Day 1 | 2.93 (1 to 6) |
Summary of primary PK parameters for alpelisib plasma concentration
| ng*hr/mL | Alpelisib + Letrozole |
|---|---|
| AUC0-24 | 38000 ± 13.2 |
| AUClast | 38000 ± 13.1 |
Summary of primary PK parameters for alpelisib plasma concentration
| ng/mL | Alpelisib + Letrozole |
|---|---|
| Alpelisib PK Parameter: Cmax at Cycle 4 Day 1 | 3260 ± 26.7 |
Summary of primary PK parameters for alpelisib plasma concentration
| hr | Alpelisib + Letrozole |
|---|---|
| Alpelisib PK Parameter: Tmax at Cycle 4 Day 1 | 2.99 (2.98 to 3) |
Summary of primary PK parameters for Letrozole plasma concentration
| ng*hr/mL | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| AUC0-24 | 433 ± 36.3 | 427 ± 28.8 |
| AUClast | 314 ± 96.9 | 347 ± 49.6 |
Summary of primary PK parameters for letrozole plasma concentration
| ng/mL | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Letrozole PK Parameter: Cmax at Cycle 1 Day 1 | 30.2 ± 33.2 | 28 ± 42.3 |
Summary of primary PK parameters for letrozole plasma concentration
| hr | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Letrozole PK Parameter: Tmax at Cycle 1 Day 1 | 1.03 (1 to 3) | 2.25 (1 to 24.5) |
Summary of primary PK parameters for Letrozole plasma concentration
| ng*hr/mL | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| AUC0-24 | 1280 ± 18 | 1810 ± 33.1 |
| AUClast | 1280 ± 17.9 | 1440 ± 66.7 |
Summary of primary PK parameters for letrozole plasma concentration
| ng/mL | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Letrozole PK Parameter: Cmax at Cycle 4 Day 1 | 75.6 ± 6.84 | 103 ± 30 |
Summary of primary PK parameters for letrozole plasma concentration
| hr | Alpelisib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Letrozole PK Parameter: Tmax at Cycle 4 Day 1 | 2 (1 to 3) | 1.17 (1 to 6) |
Summary of primary PK parameters for Buparlisib plasma concentration
| ng*hr/mL | Buparlisib + Letrozole |
|---|---|
| AUC0-24 | 6420 ± 60 |
| AUClast | 4820 ± 123 |
Summary of primary PK parameters for buparlisib plasma concentration
| ng/mL | Buparlisib + Letrozole |
|---|---|
| Buparlisib PK Parameter: Cmax at Cycle 1 Day 1 | 760 ± 86.7 |
Summary of primary PK parameters for buparlisib plasma concentration
| hr | Buparlisib + Letrozole |
|---|---|
| Buparlisib PK Parameter: Tmax at Cycle 1 Day 1 | 1.03 (0.5 to 3.5) |
Summary of primary PK parameters for Buparlisib plasma concentration
| ng*hr/mL | Buparlisib + Letrozole |
|---|---|
| Buparlisib PK Parameter: AUClast at Cycle 4 Day 1 | 10400 (10400 to 10400) |
Summary of primary PK parameters for buparlisib plasma concentration
| ng/mL | Buparlisib + Letrozole |
|---|---|
| Buparlisb PK Parameter: Cmax at Cycle 4 Day 1 | 610 (610 to 610) |
Summary of primary PK parameters for buparlisib plasma concentration
| hr | Buparlisib + Letrozole |
|---|---|
| Buparlisib PK Parameter: Tmax at Cycle 4 Day 1 | 3 (3 to 3) |
Collected over All Adverse Events reported in this record are on-treatment events (from first dose of study treatment to last dose of study treatment + 30 days, duration expected to be a total of approximately 25 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpelisib + Letrozole | 1/130 (0.8%) | 21/130 (16.2%) | 126/130 (96.9%) |
| Buparlisib + Letrozole | 0/81 (0%) | 22/81 (27.2%) | 80/81 (98.8%) |
| Placebo + Letrozole | 1/125 (0.8%) | 6/125 (4.8%) | 106/125 (84.8%) |
| Event | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/130 | 7/81 | 0/125 |
| Aspartate aminotransferase increasedInvestigations | 0/130 | 6/81 | 0/125 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/130 | 0/81 | 0/125 |
| HepatotoxicityHepatobiliary disorders | 0/130 | 3/81 | 0/125 |
| Atrial fibrillationCardiac disorders | 0/130 | 2/81 | 0/125 |
| ColitisGastrointestinal disorders | 1/130 | 2/81 | 0/125 |
| RashSkin and subcutaneous tissue disorders | 3/130 | 2/81 | 0/125 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 2/130 | 2/81 | 0/125 |
| General physical health deteriorationGeneral disorders | 2/130 | 1/81 | 0/125 |
| PyrexiaGeneral disorders | 2/130 | 0/81 | 0/125 |
| Event | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 14/130 | 49/81 | 3/125 |
| Aspartate aminotransferase increasedInvestigations | 11/130 | 44/81 | 2/125 |
| HyperglycaemiaMetabolism and nutrition disorders | 69/130 | 38/81 | 8/125 |
| DiarrhoeaGastrointestinal disorders | 66/130 | 29/81 | 19/125 |
| NauseaGastrointestinal disorders | 57/130 | 37/81 | 23/125 |
| RashSkin and subcutaneous tissue disorders | 58/130 | 31/81 | 10/125 |
| FatigueGeneral disorders | 53/130 | 30/81 | 42/125 |
| StomatitisGastrointestinal disorders | 42/130 | 18/81 | 5/125 |
| Decreased appetiteMetabolism and nutrition disorders | 40/130 | 25/81 | 10/125 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/130 | 13/81 | 34/125 |
The Full Analysis Set (FAS) comprised all randomized subjects in the study.
| Age, Continuous(Years) | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|---|
| Mean | 64.3 ± 8.53 | 65.2 ± 8.61 | 63.1 ± 8.31 | 64.1 ± 8.49 |
| Sex: Female, Male(Participants) | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|---|
| Female | 131 | 83 | 126 | 340 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alpelisib + Letrozole | Buparlisib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|---|
| White | 117 | 68 | 105 | 290 |
| Asian | 7 | 4 | 10 | 21 |
| Black or African American | 3 | 3 | 5 | 11 |
| Other | 3 | 6 | 3 | 12 |
| Unknown | 1 | 2 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2014 to primary completion in Jul 2017, 39 months.
Results were first posted in Sep 2018, 1 year 2 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Buparlisib